Get the Stockscreener App
3.09
1.31%
0.04
Absci Corp stock is traded at $3.09, with a volume of 1.63M.
It is up +1.31% in the last 24 hours and down -3.74% over the past month.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
See More
Previous Close:
$3.05
Open:
$3.04
24h Volume:
1.63M
Relative Volume:
0.36
Market Cap:
$393.52M
Revenue:
$4.21M
Net Income/Loss:
$-97.67M
P/E Ratio:
-3.3226
EPS:
-0.93
Net Cash Flow:
$-70.76M
1W Performance:
+25.87%
1M Performance:
-3.74%
6M Performance:
-23.13%
1Y Performance:
-41.59%
1-Day Range:
$2.96
$3.12
1-Week Range:
$2.6203
$3.298
52-Week Range:
$2.01
$6.33
Absci Corp Stock (ABSI) Company Profile
Name
Absci Corp
Sector
Industry
Phone
(360) 949-1041
Address
18105 SE MILL PLAIN BLVD, VANCOUVER
Compare ABSI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABSI
Absci Corp
|
3.09 | 393.52M | 4.21M | -97.67M | -70.76M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Absci Corp Stock (ABSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-25 | Initiated | Needham | Buy |
| Oct-02-24 | Initiated | Guggenheim | Buy |
| Jul-03-24 | Initiated | Morgan Stanley | Overweight |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| May-04-23 | Initiated | H.C. Wainwright | Buy |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Underweight |
| Jul-18-22 | Initiated | Truist | Buy |
| Mar-02-22 | Resumed | Cowen | Market Perform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Nov-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Aug-16-21 | Initiated | BofA Securities | Neutral |
| Aug-16-21 | Initiated | Cowen | Market Perform |
| Aug-16-21 | Initiated | Credit Suisse | Outperform |
| Aug-16-21 | Initiated | Stifel | Hold |
View All
Absci Corp Stock (ABSI) Latest News
Absci (NASDAQ:ABSI) Price Target Raised to $9.00 at KeyCorp - MarketBeat
Absci price target raised to $9 from $5 at KeyBanc - TipRanks
Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025 - GlobeNewswire
AI Drug Pioneer Absci Reveals Q1 2025 Results Date: Key Updates Coming May 13 - Stock Titan
Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing - Benzinga
Absci (NASDAQ:ABSI) Earns Buy Rating from Needham & Company LLC - MarketBeat
Raymond James Financial Inc. Acquires Shares of 193,926 Absci Co. (NASDAQ:ABSI) - MarketBeat
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday - Benzinga
Health Care Technology Stocks Surge After FDA Announces Plans To Phase Out Animal Testing Requirements - Benzinga
Absci Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) - Benzinga
ADAR1 Capital Management LLC Has $413,000 Position in Absci Co. (NASDAQ:ABSI) - MarketBeat
Absci Corporation: A Potential Turnaround Play In Biotech Amid A Tumultuous Market - Seeking Alpha
Top 5 AI & Digital Biotech Companies (April 2025) - Securities.io
Absci stock touches 52-week low at $2.45 amid market challenges - Investing.com
Absci stock touches 52-week low at $2.45 amid market challenges By Investing.com - Investing.com South Africa
Which Healthcare Stock Is the Best Buy Right Now? - MarketBeat
Absci to Participate in Upcoming Investor Conferences - MarketScreener
AI Drug Pioneer Absci Takes Center Stage at Two Elite Healthcare Conferences - Stock Titan
Royce & Associates LP Grows Stake in Absci Co. (NASDAQ:ABSI) - MarketBeat
HC Wainwright Issues Negative Estimate for Absci Earnings - MarketBeat
Absci Corp’s Earnings Call: Balancing Innovation and Financial Challenges - MSN
KeyBanc maintains Absci stock Overweight rating, $5 target By Investing.com - Investing.com South Africa
KeyBanc maintains Absci stock Overweight rating, $5 target - Investing.com
Platinum Investment Management Ltd. Boosts Holdings in Absci Co. (NASDAQ:ABSI) - MarketBeat
Absci (NASDAQ:ABSI) Given "Buy" Rating at HC Wainwright - MarketBeat
Absci (NASDAQ:ABSI) Given Buy Rating at Needham & Company LLC - MarketBeat
Absci (NASDAQ:ABSI) Releases Quarterly Earnings Results - MarketBeat
Absci (NASDAQ:ABSI) Announces Earnings Results - MarketBeat
Absci Corporation (NASDAQ:ABSI) Q4 2024 Earnings Call Transcript - Insider Monkey
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen - Benzinga
Absci Corp (ABSI) Q4 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus
Nikko Asset Management Americas Inc. Boosts Stock Position in Absci Co. (NASDAQ:ABSI) - MarketBeat
H.C. Wainwright maintains $7 target on Absci stock with Buy rating - Investing.com Australia
Earnings call transcript: Absci Q4 2024 revenue misses, stock dips By Investing.com - Investing.com Australia
Absci Posts Downbeat Results, Joins HealthEquity, Tonix Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
A Glimpse Into The Expert Outlook On Absci Through 7 Analysts - Benzinga
Why StoneCo Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket - Benzinga India
Absci Corp (ABSI) Q4 2024 Earnings Call Highlights: Strategic Collaborations and Financial ... By GuruFocus - Investing.com Canada
Absci Corp Stock (ABSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):